Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
rcolepsy - Overview
rcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
rcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
rcolepsy - Companies Involved in Therapeutics Development
Axsome Therapeutics Inc
Bioprojet SCR
Centessa Pharmaceuticals Plc
ConSynce Therapeutics Inc
F. Hoffmann-La Roche Ltd
Gubra ApS
Inexia Ltd
Jazz Pharmaceuticals Plc
KemPharm Inc
Lennham Pharmaceuticals Inc
NLS Pharmaceutics AG
Ono Pharmaceutical Co Ltd
Seelos Therapeutics, Inc.
SK Biopharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
Synchronicity Pharma Inc
Takeda Pharmaceutical Co Ltd
Theranexus SA
Vallon Pharmaceuticals Inc
XWPharma Ltd
rcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALKS-2680 - Drug Profile
Product Description
Mechanism Of Action
History of Events
davorexton - Drug Profile
Product Description
Mechanism Of Action
History of Events
dextroamphetamine IR - Drug Profile
Product Description
Mechanism Of Action
History of Events
DSP-0187 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GUI-36 - Drug Profile
Product Description
Mechanism Of Action
HBS-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-1077 - Drug Profile
Product Description
Mechanism Of Action
mazindol ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLS-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONO-2909 - Drug Profile
Product Description
Mechanism Of Action
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
OX2 agonist - Drug Profile
Product Description
Mechanism Of Action
History of Events
OX2 agonist (Oral) - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oxybate - Drug Profile
Product Description
Mechanism Of Action
Peptides to Agonize Orexin 2 Receptor for rcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
pitolisant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
reboxetine - Drug Profile
Product Description
Mechanism Of Action
History of Events
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
History of Events
samelisant - Drug Profile
Product Description
Mechanism Of Action
History of Events
SLS-010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize ADORA for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
solriamfetol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ulotaront - Drug Profile
Product Description
Mechanism Of Action
History of Events
valiloxybate - Drug Profile
Product Description
Mechanism Of Action
History of Events
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
rcolepsy - Dormant Projects
rcolepsy - Discontinued Products
rcolepsy - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: NLS pharmaceutics announces positive opinion from European Regulators to grant Orphan Drug Desigtion for Mazindol ER in idiopathic hypersomnia
Jun 28, 2022: Axsome Therapeutics hosts Sunosi investor update virtual event today with Key Opinion Leaders
Jun 28, 2022: Axsome Therapeutics to host Sunosi investor update virtual event
Jun 08, 2022: Harmony Biosciences presents post-hoc alysis of WAKIX (pitolisant) pivotal data in adults with high burden of rcolepsy symptoms
Jun 02, 2022: NLS Pharmaceutics announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of rcolepsy
May 12, 2022: Vallon Pharmaceuticals reports additiol pharmacokinetic and pharmacodymic data from SEAL study of ADAIR
May 04, 2022: NLS Pharmaceutics achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with rcolepsy
Mar 28, 2022: NLS Pharmaceutics announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER
Mar 16, 2022: NLS Pharmaceutics announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with rcolepsy
Feb 23, 2022: KemPharm completes KP1077 Pre-IND meeting process with FDA
Feb 07, 2022: NLS Pharmaceutics to present interim top-line data for Quilience (Mazindol ER) in patients with rcolepsy at the World Sleep Congress in March 2022
Feb 07, 2022: Aculys Pharma begins Japan PI for rcolepsy drug candidate
Dec 13, 2021: Harmony Biosciences publishes pitolisant efficacy data in CNS Drugs
Nov 18, 2021: tiol Institute for Health and Care Excellence (NICE) issues positive guidance for Jazz Pharmaceuticals’ Sunosi (solriamfetol) for the treatment of adults with excessive daytime sleepiness (EDS) caused by rcolepsy
Oct 06, 2021: Takeda to stop Phase II trials of TAK-994 due to safety sigl
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Narcolepsy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Narcolepsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Narcolepsy - Pipeline by Axsome Therapeutics Inc, 2022
Narcolepsy - Pipeline by Bioprojet SCR, 2022
Narcolepsy - Pipeline by Centessa Pharmaceuticals Plc, 2022
Narcolepsy - Pipeline by ConSynance Therapeutics Inc, 2022
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Narcolepsy - Pipeline by Gubra ApS, 2022
Narcolepsy - Pipeline by Inexia Ltd, 2022
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, 2022
Narcolepsy - Pipeline by KemPharm Inc, 2022
Narcolepsy - Pipeline by Lennham Pharmaceuticals Inc, 2022
Narcolepsy - Pipeline by NLS Pharmaceutics AG, 2022
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Narcolepsy - Pipeline by Seelos Therapeutics, Inc., 2022
Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Narcolepsy - Pipeline by Sumitomo Pharma Co Ltd, 2022
Narcolepsy - Pipeline by Sunovion Pharmaceuticals Inc, 2022
Narcolepsy - Pipeline by Suven Life Sciences Ltd, 2022
Narcolepsy - Pipeline by Synchronicity Pharma Inc, 2022
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Narcolepsy - Pipeline by Theranexus SA, 2022
Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, 2022
Narcolepsy - Pipeline by XWPharma Ltd, 2022
Narcolepsy - Dormant Projects, 2022
Narcolepsy - Dormant Projects, 2022 (Contd..1)
Narcolepsy - Discontinued Products, 2022